Explain the Role of the New Opioid Apadaz

January 2020

Apadaz (AP-uh-daz) will be a new opioid combo for acute pain.

Apadaz oral tablets contain acetaminophen plus benzhydrocodone...a prodrug that's converted to hydrocodone by enzymes in the gut.

But FDA denied approval of Apadaz as an "abuse-deterrent" opioid. It doesn't seem less likely to be abused than hydrocodone.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Table of Contents

Gastroenterology Optimize PPI Dosing for Nonvariceal Upper GI Bleeds
Biosimilars Answer Questions About Biosimilars
Emergency Medicine Create Pathways to Promote Non-Opioids for Pain in Your ED
Cultural Awareness Enhance Communication About Gender Preferences
HIV & AIDS Be Ready to Start Nonoccupational HIV Post-Exposure Prophylaxis (PEP)
Stroke Continue to Start With High-Intensity Statins in Most Stroke Patients
COPD Know How Eosinophil Counts May Guide Inhaled Steroids for COPD
New Drugs Explain the Role of the New Opioid Apadaz
Hypertension Advise Patients at Discharge About Timing of Their BP Meds
New Drugs Stay Alert for the New Narcolepsy Meds Solriamfetol and Pitolisant